Pathobiotek Reports That It Will Present At the `Seventh Annual Blood Product Safety Conference'.Health/Medical Writers HOUSTON--(BUSINESS WIRE)--Sept. 14, 2000 Pathobiotek Diagnostics Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PBTK)(http://www.pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced the acceptance of an invitation to present at the "Seventh Annual Blood Product Safety Conference", Feb. 5-7, 2001 at the Ritz Carlton -- Tyson's Corner -- McLean, Va. The conference is sponsored by the Cambridge Healthtech Institute, www.healthtech.com . The title of the presentation will be "The Human Bloodstream Is Not Sterile." A brief description of the presentation, according to Dr. Kathleen MacPhee, director of R&D at Pathobiotek: "We developed techniques that allow us to detect continuous bacteremia Continuous bacteremia A kind of bacteremia where bacteria is always in the blood. Mentioned in: Blood Culture in the blood of healthy individuals. After isolating nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. from both serum samples and cultures, the gram negative bacterium was identified using PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) and DNA sequence DNA sequence Genetics The precise order of bases–A,T,G,C–in a segment of DNA, gene, chromosome, or an entire genome. See Base pair, Base sequence analysis, Chromosome, Gene, Genome. analyses. In situ hybridizations in situ hybridization A method for localizing a sequence of DNA, mRNA, or protein in a cell or tissue; the use of a DNA or RNA probe to detect a cDNA sequence in chromosome spreads or in interphase nuclei or an RNA sequence of cloned bacterial or cultured confirmed the presence of metabolically active bacteria in both human serum and cultures. The implications of these data will be discussed." The audience will consist of a portion of the target market for Pathobiotek products as well as medical professionals with an interest in the information provided relative to a bloodborne organism. The exposure and challenges are expected to broaden interest in the Luey technology and its potential as a product for the pharmaceutical and medical diagnostic industries. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for Forward-Looking Statements: Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the company's domestic and international operations, imprecision in estimating product reserves and the company's ability to replace and expand its holdings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion